Author: Willem van Lawick

~ Significant reduction in Transplant Related Mortality and improvement in Overall Survival observed in comparison to an observational control group ~ ~ Zero patients developed grade III-IV acute Graft-versus-Host-Disease upon infusion of ATIR101™ ~ Amsterdam, The Netherlands, December 6, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a… Continue reading Kiadis Pharma presents positive 1-year follow-up data of its pivotal Phase II trial with ATIR101™

– Respiratory Syncytial Virus (RSV), a common contagious lung infection, is a global health threat responsible for up to 200,000 deaths worldwide annually – UK Phase I trial supported with EUR 3.44 m from Wellcome Trust, taking place at Imperial College, London Groningen, the Netherlands, November 7, 2016 – Mucosis B.V., a clinical stage biotechnology… Continue reading Mucosis Initiates First-in-Human Study of SynGEM®, a Needle-Free Nasal Spray RSV Vaccine

Amsterdam, The Netherlands, November 3, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that data from the Company’s ongoing Phase II clinical trial (NCT01794299/EudraCT 2012-004461-41) with its lead product… Continue reading One year data from Kiadis Pharma’s ongoing Phase II trial with ATIR101™ will be presented at the American Society of Hematology 2016 Annual Meeting

London. 10 October 2016, 09.00 AM BST. Norgine Ventures announced that it has provided financing of up to €3 million to PulseCath B.V.. This investment recognises the unique positioning of PulseCath’s cardiac assist devices and the growth potential of the company. PulseCath, based in the Netherlands, develops and commercialises innovative left ventricle assist devices. The… Continue reading Norgine Ventures completes €3 Million Financing With PulseCath

~ LLS makes second equity investment in Kiadis Pharma for the Phase II development ~ Amsterdam, The Netherlands, July 11, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that… Continue reading Kiadis Pharma and The Leukemia & Lymphoma Society strengthen partnership around the development of ATIR101™ in ALL and AML patients